|Bid price||8.00||Open price||7.75|
|Ask price||8.15||Prev close||8.15|
Register now for FREE live Oxford BioMedica share prices, Oxford BioMedica stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Oxford BioMedica Level 2 Data, indepth research tools and investor commentary for Oxford BioMedica (OXB) and other London Stock Exchange equities.
Register now for FREE Oxford BioMedica share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB0006648157|
|Activites||Oxford BioMedica plc is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp.||Index||n/a|
|Latest Share Price (p)||8.15||Net Gearing (%)||-10.14|
|Market Capitalisation (£m)||205.49||Gross Gearing (%)||31.85|
|Shares in issue (m)||2,568.59||Debt Ratio||6.25|
|P/E Ratio||-18.61||Debt-to-Equity Ratio||0.14|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.47|
|Dividend Yield (%)||0.00||Price to book value||8.92|
|Dividend cover (x)||0.00||ROCE||-0.54|
|Earning per share (p)||-0.43||EPS Growth (%)||45.57|
|52 week high / low||13.25 / 3.38||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
Oxford BioMedica (LSE: OXB), ("OXB" or "the Group") a leading gene and cell therapy group, has announced that for the six months ended 30 June 2015 revenue was Â£4.4m (H1 2014: Â£4.7 million) due in large part to the Novartis contract. The net loss was Â£6.1m (H1 2014: Â£4.8m). Research and...
/* */ RNS Number : 2197X Oxford Biomedica PLC 27 August 2015 OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2015 Oxford, UK - 27 August 2015: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the Group") a leading gene and cell...
/* */ RNS Number : 3766V Oxford Biomedica PLC 06 August 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are...
Register now for FREE Oxford BioMedica company news
OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles. So here is a new title This one has got the charts at the top again & has a link to the old one....
Very strong rumours of a further predator around. CAT,WYEYH,JOHNSON&JOHNSON,MERCK to name a few.............could be an exciting week ...!
Very strong rumours of a further predator.........CAT,JOHNSON&JOHNSON,WYETH,MERCK to name a few. Could be an interesting week..!
Register now for FREE Oxford BioMedica share price discussions